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Abstract
Background: Immunoglobulin A (IgA) secretion in saliva decreases with age and may be the cause of increased
vulnerability of the elderly to respiratory infections. The effect of oral intake of lactic acid bacteria on salivary
secretory IgA (SIgA) in the elderly has not been reported. The objective of this study was to demonstrate the
acceleration of salivary SIgA secretion by oral intake of Lactobacillus pentosus strain b240 (b240) in the elderly.
Results: A total of 80 healthy elderly individuals were randomly allocated to either an intervention (i.e., b240) or a
control (i.e., placebo) group. The elderly individuals in the b240 group were given a sterile water beverage (125
mL) containing heat-killed b240 (4 × 10
9 cells), while those in the placebo group were given only a sterile water
beverage (125 mL); both groups received their respective beverages once daily for 12 weeks. Saliva was collected
before initiation of the study and every 2 weeks thereafter. Saliva flow rate and SIgA concentration were
determined, and the SIgA secretion rate was calculated. The mean salivary SIgA secretion rate in the b240 group
steadily increased until week 4 (exhibiting a 20% elevation relative to that at week 0), and then remained stable
until week 12. Changes in SIgA secretion rate over the intervention period were significantly greater in the b240
group than in the placebo group. The treatment groups exhibited no significant differences in adverse events.
Conclusions: Oral intake of L. pentosus strain b240 for 12 weeks significantly accelerated salivary SIgA secretion,
thereby indicating its potential utility in the improvement of mucosal immunity and resistance against infection in
the elderly.
Background
The human body has various defense mechanisms
against pathogenic microorganisms. The mucosal mem-
branes covering the oral cavity, gastrointestinal, respira-
tory, and genitourinary tracts are continuously exposed
to pathogenic microorganisms and they are protected
by a large and highly specialized innate and adaptive
mucosal immune system [1]. The adaptive humoral
immune defense at mucosal surfaces is to a large extent
mediated by secretory immunoglobulin A (SIgA), the
predominant immunoglobulin class in human external
secretion [2]. Adaptive humoral mucosal immune
responses are mainly initiated in an inductive site (e.g.,
Peyer’s patch in intestine). Sensitized mucosal immuno-
cytes (e.g., IgA
+ B cells) then leave the inductive site,
travel through the lymph, enter the circulation, and
migrate to diffuse mucosal effector sites (e.g., lamina
propria), where they differentiate into memory or effec-
tor cells (e.g., IgA-producing plasma cells) [3,4]. SIgA in
saliva has been widely used as an indicator of mucosal
immunity [5]. The salivary glands are the most impor-
tant source of SIgA in the upper respiratory tract [6]. A
lack of non-specific SIgA at the mucosal surface or the
inability to produce specific SIgA can lead to an
increased risk of infection [7].
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mortality and significant morbidity in the elderly, who
are at greater risk than the younger population [8].
Increasing age has been associated with a decline in
humoral and cell-mediated immunity against newly
encountered pathogens or vaccines [9-13], thus creating
a need for countermeasures against age-related immune
dysfunctions. SIgA secretion in saliva decreases with age
[14-18], and may lead to an increased risk of respiratory
infections. Therefore, improving or slowing the age-
related decline of salivary SIgA may be beneficial for
improving the health of the elderly.
Recently, many lactic acid bacteria have been reported
to modulate specific/non-specific immune responses
[19]. Certain species have been documented to enhance
IgA secretion/concentration in the gut of mice [20], the
feces of healthy children [21], and the saliva of infants
[22]. However, no studies have been conducted on the
augmentation of salivary SIgA secretion in the elderly.
Lactobacillus pentosus strain b240 (b240) is an anaero-
bic non-sporulating gram-positive bacterium, originally
isolated from fermented tea leaves [23]. Initially, on the
basis of a carbohydrate-fermentation test and informa-
tion from 16 S rRNA gene sequencing, this bacterium
was identified as Lactobacillus plantarum. Recently,
Bringel et al. [24] proposed its reclassification as L. pen-
tosus on the basis of the recA gene sequence. Following
this proposal, the gene sequence of b240 was analyzed
in detail (data not shown) and formally classified as L.
pentosus. In our laboratory, we have demonstrated b240
enhancement of IgA production from Peyer’s patch cells
in the mouse gut [25]. We have further determined that
the oral intake of heat-killed b240 (corresponding to 2 ×
10
9 or 2 × 10
10 CFU/day for 3 weeks) significantly ele-
vates salivary IgA secretion rate and the amount of fecal
IgA (but not significantly) in younger adults [26]. Taken
together, these results indicate that b240 intake may
increase salivary SIgA secretion via activation of the gut
mucosal immune system. The objective of this study
was to verify the hypothesis that oral intake of b240 is
effective in enhancing salivary SIgA secretion in the
elderly.
Results
Subject characteristics
The clinical features of the individuals who participated
in this randomized control study at the initial (pre-inter-
vention) and final (post-intervention) visits are shown in
Table 1. There were no significant differences between
the b240 and placebo groups with respect to age, height,
weight, serum cortisol levels, saliva chromogranin A/
total protein ratio, stress, total energy expenditure, and
energy intake.
Overall changes in salivary variables
The mean absolute values for the 3 indices, salivary
SIgA secretion rate, SIgA concentration, and saliva
flow rate over the course of intervention are shown in
Table 2. There were no significant differences between
the b240 and placebo groups by statistical analysis of
multiple-factor analysis of variance (ANOVA; factors:
group, gender, period of intake, frequency of saliva col-
lection). The salivary SIgA secretion rate at week 0 was
subject to wide inter-individual variation (range, 87-
674 μg/5 min; median, 296 μg/5 min). The averages of
the individual changes in the saliva flow rate, SIgA
concentration, and SIgA secretion rate over time (mea-
surement at each visit minus individual baseline mea-
surement) are shown in Figure 1, 2 and 3, respectively.
The initial indices, saliva flow rate, SIgA concentration,
and SIgA secretion rate were confirmed by the t-test as
being statistically identical between the 2 groups. The
average individual changes of saliva flow rate (Figure
1) and SIgA secretion rate (Figure 3) were increased in
both groups. In contrast, average SIgA concentration
decreased in the placebo group, while it increased in
the b240 group until 4 weeks and returned to a prior
level (Figure 2). The average individual changes of sal-
iva flow rate were found to be significantly higher in
the b240 group than in the placebo group at weeks 4
and 6 (P = 0.013 and P = 0.002, respectively). Likewise,
the average SIgA concentrations were higher at weeks
2, 4, and 12 (P =0 . 0 1 0 ,P =0 . 0 3 0 ,a n dP =0 . 0 3 7 ,
respectively) and the average SIgA secretion rates were
higher at weeks 4 and 12 (P =0 . 0 2 4a n dP =0 . 0 4 2 ,
respectively). Most importantly, the statistical multiple-
factor ANOVA (factors: group, gender, period of
intake, and frequency of saliva collection) revealed a
significant elevation of all indices in the b240 group
over those of the placebo group. The P values for
group, gender, period of intake, and frequency of saliva
collection period, respectively, are as follows: for saliva
flow rate: <0.001, 0.790, <0.001, and 0.438; for SIgA
concentration: <0.001, 0.161, 0.003, and 0.001; and for
SIgA secretion rate: <0.001, 0.168, 0.594, and 0.770
(Figure 1, 2 and 3). In the b240 group, the mean SIgA
secretion rate steadily increased by week 4 to 20%
greater than at week 0, after which it remained stable
until week 12.
Blood chemistry and adverse events
There were no significant differences in the blood
chemistry profiles of the b240 and placebo groups as
measured during pre-and post-intervention visits (Table
3). Accumulated incidences of adverse symptoms during
the intervention did not differ significantly between
groups (Table 4).
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The major finding of this study was that, compared to
placebo, the oral intake of L. pentosus strain b240 (4 ×
10
9 cells) for 12 weeks resulted in higher SIgA secretion
rate in the elderly. This is the first report to show that
salivary SIgA in the elderly can be augmented by sup-
plementation with lactic acid bacteria.
The elevated SIgA secretion rate in the b240 group
reached a plateau at week 4, suggesting that b240 intake
continuously elevates the rate of SIgA secretion during
the first month. Thereafter, the SIgA secretion rate
remained stable from week 4 until week 12, suggesting
that continuous daily intake of b240 may be efficacious
for the maintenance of increased of salivary SIgA in the
elderly.
How did oral intake of b240 lead to an augmentation
of salivary SIgA? Within the mucosal immune system,
there is a significant degree of compartmentalization
linking specific mucosal inductive sites with particular
effector sites (e.g., the gut with mammary and salivary
Table 1 Subject characteristics of the b240 and placebo groups before and after the 12-week study
Pre-intervention test Post-intervention test
Placebo group b240 group
2 P value Placebo group b240 group
2 P value
Number of subjects (male/female) 35 (9/26) 38 (10/28)
Age (y) 71 ± 5 71 ± 5 0.846
Height (cm) 155 ± 8 154 ± 6 0.497 - -
Body weight (kg) 55.3 ± 8.7 55.5 ± 6.8 0.916 - -
BMI (kg/m
2) 22.9 ± 2.8 23.4 ± 2.5 0.447 - -
Serum cortisol (μg/dL) 12.0 ± 3.6 11.3 ± 3.6 0.403 11.3 ± 3.2 10.9 ± 4.6 0.721
Saliva chromogranin A/total protein ratio 7.7 ± 5.1 9.7 ± 7.5 0.186 9.1 ± 7.3 9.2 ± 6.0 0.920
POMS
1 (points)
Tension-Anxiety 48 ± 8 50 ± 10 0.289 48 ± 8 49 ± 9 0.751
Depression-Dejection 52 ± 10 53 ± 11 0.900 51 ± 10 51 ± 10 0.727
Anger-Hostility 51 ± 10 51 ± 8 0.999 49 ± 8 49 ± 9 0.796
Vigor 51 ± 7 53 ± 8 0.193 51 ± 9 53 ± 8 0.344
Fatigue 50 ± 9 52 ± 10 0.301 51 ± 10 52 ± 11 0.583
Confusion 51 ± 8 51 ± 11 0.963 50 ± 10 52 ± 9 0.516
Energy expenditure (kcal/day) 1900 ± 327 1939 ± 296 0.591 1959 ± 335 1969 ± 298 0.892
Energy intake (kcal/day) 2003 ± 525 1948 ± 620 0.685 2008 ± 607 1934 ± 653 0.618
Protein/Total energy intake (%) 16.9 ± 3.6 16.8 ± 2.7 0.883 16.8 ± 2.5 16.5 ± 2.8 0.644
Fat/Total energy intake (%) 28.6 ± 5.1 28.4 ± 5.1 0.881 28.7 ± 4.7 28.0 ± 5.4 0.568
Carbohydrate/Total energy intake (%) 51.2 ± 6.8 52.3 ± 5.8 0.444 51.5 ± 6.3 52.8 ± 5.7 0.385
Mean (SD); P value, by unpaired t-test.
1POMS, Profile of Mood States.
24×1 0
9 cells of heat-killed L. pentosus strain b240 per day for 12 weeks.
Table 2 SIgA secretion rate, SIgA concentration, and saliva flow rate in the b240 and placebo groups
Placebo group
Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
n 7 06 86 66 46 26 06 0
SIgA secretion rate
2 (μg/5 min) 319 ± 16 337 ± 21 333 ± 20 343 ± 21 348 ± 23 363 ± 22 334 ± 20
SIgA concentration (μg/mL) 173 ± 13 170 ± 11 161 ± 12 159 ± 11 157 ± 11 165 ± 12 154 ± 11
Saliva flow rate (mL/5 min) 2.5 ± 0.2 2.4 ± 0.2 2.7 ± 0.2 2.7 ± 0.2 2.8 ± 0.2 2.8 ± 0.2 2.9 ± 0.2
b240 group
1
Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
n 76 75 70 72 62 70 66
SIgA secretion rate
2 (μg/5 min) 297 ± 14 330 ± 20 357 ± 23 364 ± 27 366 ± 30 352 ± 23 359 ± 24
SIgA concentration (μg/mL) 147 ± 8 165 ± 10 156 ± 9 149 ± 11 134 ± 8 144 ± 8 149 ± 9
Saliva flow rate (mL/5 min) 2.3 ± 0.1 2.3 ± 0.2 2.6 ± 0.2 2.9 ± 0.2 3.0 ± 0.2 2.8 ± 0.2 2.7 ± 0.2
Mean ± SEM; n, number of saliva sample; SIgA; secretory immunoglobulin A.
14×1 0
9 cells of heat-killed L. pentosus strain b240 per day for 12 weeks.
2SIgA secretion rate, which was calculated by multiplying SIgA concentration by saliva flow rate.
Kotani et al. Immunity & Ageing 2010, 7:11
http://www.immunityageing.com/content/7/1/11
Page 3 of 11glands), which is partially due to the differential expres-
sion of chemokines, integrins and cytokines among
mucosal tissues [3,4]. In line with this study, the oral
intake of polybacterial immunomodulator Dentavax,
containing killed Lactobacillus acidophilus, has been
reported to induce a strain-specific IgA response in the
saliva of healthy adults [27]. Likewise, the oral intake of
fermented milk containing L. casei DN-114 001 has
been shown to induce non-specific total SIgA in infant
saliva [22]. One plausible hypothesis is that the oral
intake of b240 stimulates the gut mucosal immune
system to enhance secretion of SIgA in saliva.
Saliva is an easily retrievable sample material and can
be collected non-invasively. Thus, salivary SIgA has
been widely used to assess the status of the mucosal
immune system. There are 2 main outcome measures
for evaluation of salivary SIgA: secretion rate and con-
centration. In this study, we focused on the SIgA
Figure 1 Changes in saliva flow rate. Changes in the saliva flow rate of subjects during the 12-week study with L. pentosus strain b240 (b240)
beverage (closed circle) or placebo (open circle). Data are represented by mean ± SEM. The difference between the b240 and placebo groups
was evaluated by multiple-factor ANOVA (factors: group, gender, period of intake, and frequency of saliva collection).
Figure 2 Changes in salivary SIgA concentration. Changes in the salivary SIgA concentration of subjects during the 12-week study with L.
pentosus strain b240 (b240) beverage (closed circle) or placebo (open circle). Data are represented by mean ± SEM. The difference between the
b240 and placebo groups was evaluated by multiple-factor ANOVA (factors: group, gender, period of intake, and frequency of saliva collection).
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SIgA available on the mucosal surfaces for protection
against pathogens [28]. Furthermore, Fahlman et al. [29]
argued that, of all the various methods commonly
employed for SIgA assessment, the SIgA secretion rate
is the most useful clinical biomarker for predicting the
incidence of upper respiratory tract infections (URTIs)
using 8 separate stepwise multiple regression analyses.
According to two longitudinal (about 1-year) studies of
elite athletes, decreased levels of salivary SIgA secretion
were associated with an increased risk for URTI; in
these studies, mean SIgA secretion relative to baseline
was reduced by 25-28% over the course of observation
[29,30]. In the present study, b240 intake for 12 weeks
produced a 20% increase in SIgA secretion rate relative
to baseline in a group of elderly participants, thereby
indicating potential clinical relevance.
In the present study, we used heat-killed b240. Heat-
killed bacteria were chosen over viable bacteria for two
reasons. First, our previous animal experiments have
shown that mouse Peyer’s patch cells, when treated with
viable or heat-killed b240 for 21 days produced approxi-
mately the same level of IgA [25]. Second, our previous
human study demonstrated that the oral intake of heat-
killed b240 enhanced salivary IgA secretion in younger
adults [26]. Several earlier studies support the view that
viability is not necessary to achieve probiotic immuno-
modulatory effects [31,32]. However, further studies are
needed to compare the effectiveness of heat-killed and
viable b240 in terms of clinical application in the elderly.
This study has several methodological strengths. First,
minimization of intra-individual variations in SIgA
secretion rate was achieved by selecting non-smoking
subjects and by collecting saliva samples throughout the
intervention period at the same time of the day, when
the salivary SIgA secretion rate is stable [33]. The sali-
vary SIgA secretion rate generally shows wide inter- and
intra-individual variation [16,17,33-36]. Our procedures
enabled us to monitor the resting state of salivary SIgA
secretion while minimizing potential errors. Second, we
adopted the suction method for collecting saliva sam-
ples. There have been many studies on salivary SIgA
that have used different sampling methods [37-40].
Michishige et al. [37] compared 3 saliva collection meth-
ods–spitting, suction, and swab methods–and concluded
that the suction method is ideal for obtaining a stable
saliva profile. Prior to this study, we compared the sali-
vary SIgA secretion rate in younger adults and the
elderly using the suction and swab methods. The suc-
tion method provided more stable results than the swab
method [unpublished results]. Third, we successfully
controlled the measured (age, gender, stress, energy
intake, energy expenditure, etc.) and non-measured con-
founders, which could affect study results.
During the intervention, the saliva flow rate per 5 min
(mL/5 min) was elevated in both groups. Saliva flow
rate has been reported to show seasonal variations
[41,42]. Takaoka et al. [41] noted that unstimulated
whole saliva volume increases during spring, reaches a
plateau in summer, and decreases from autumn to win-
ter. Since the present study was performed from Febru-
ary to May, this seasonal variation may explain why the
saliva volume increased during the trial. Compared with
the placebo group, the b240 group had a greater
Figure 3 Changes in salivary SIgA secretion rate. Changes in the salivary SIgA secretion rate of subjects during the 12-week study with L.
pentosus strain b240 (b240) beverage (closed circle) or placebo (open circle). Data are represented by mean ± SEM. The difference between the
b240 and placebo groups was evaluated by multiple-factor ANOVA (factors: group, gender, period of intake, and frequency of saliva collection).
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expected as a result of the stimulatory effect of b240. It
has been reported that the SIgA concentration in saliva
is negatively correlated with the saliva flow rate [5], pos-
sibly explaining why the placebo group exhibited a
decrease in SIgA levels during the trial. In the b240
group, despite the fact that the saliva flow rate increased
relative to that of the placebo group, the SIgA concen-
tration increased until week 4 relative to its initial value
and returned to a prior level. This could be explained
by the enhanced seasonal salivary secretion effect.
Taken together, these results indicated that the intake of
b240 elevates the salivary SIgA secretion rate by stimu-
lating not only the saliva flow rate but also SIgA
production.
Table 3 Comparison of blood variables at pre- and post-intervention between the b240 and placebo groups
Pre-intervention Post-intervention
Blood variable Placebo group
(n = 40)
b240 group
1
(n = 40)
P value Placebo group
(n = 40)
b240 group
1
(n = 40)
P value
Total protein (g/dL) 7.4 ± 0.4 7.2 ± 0.6 0.137 7.3 ± 0.4 7.2 ± 0.5 0.413
Albumin (g/dL) 4.4 ± 0.2 4.3 ± 0.2 0.115 4.4 ± 0.2 4.3 ± 0.3 0.381
Albumin/
globulin ratio
1.5 ± 0.2 1.5 ± 0.2 0.733 1.5 ± 0.2 1.5 ± 0.2 0.744
Total cholesterol (mg/dL) 221 ± 29 219 ± 35 0.722 221 ± 30 223 ± 37 0.814
Triglyceride (mg/dL) 105 ± 51 99 ± 53 0.631 101 ± 53 103 ± 50 0.895
Free fatty acid (mEq/L) 0.6 ± 0.2 0.6 ± 0.2 0.126 0.5 ± 0.2 0.5 ± 0.2 0.166
Fasting glucose (mg/dL) 95 ± 13 92 ± 12 0.355 95 ± 16 94 ± 16 0.863
Hemoglobin A1c (%) 5.2 ± 0.4 5.3 ± 0.4 0.536 5.3 ± 0.4 5.4 ± 0.4 0.663
Aspartate amino-transferase (U/L) 24.5 ± 7.2 25.7 ± 9.1 0.506 23.1 ± 8.6 23.6 ± 9.5 0.825
Alanine amino-transferase (U/L) 18.9 ± 7.9 20.4 ± 7.5 0.387 18.1 ± 10.1 18.3 ±7.2 0.939
g-Glutamyl transpeptidase (U/L) 27.8 ± 18.3 28.7 ± 26.2 0.863 27.1 ± 21.4 29.4 ± 34.9 0.724
Alkaline phosphatase (U/L) 258 ± 74 265 ± 131 0.763 245 ± 67 262 ± 143 0.506
Lactate dehydrogenase (U/L) 216 ± 51 205 ± 62 0.386 194 ± 25 184 ± 27 0.113
Choline- esterase (U/L) 340 ± 50 328 ± 47 0.258 325 ± 48 319 ± 48 0.619
Total bilirubin (mg/dL) 0.6 ± 0.2 0.7 ± 0.3 0.058 0.7 ± 0.2 0.7 ± 0.3 0.315
Direct bilirubin (mg/dL) 0.2 ± 0.0 0.2 ± 0.1 0.122 0.2 ± 0.1 0.2 ± 0.1 0.752
Indirect bilirubin (mg/dL) 0.5 ± 0.1 0.5 ± 0.2 0.078 0.5 ± 0.2 0.6 ± 0.2 0.241
Urea nitrogen (mg/dL) 14.8 ± 3.6 15.1 ± 3.6 0.695 15.7 ± 4.5 15.9 ± 3.5 0.846
Uric acid (mg/dL) 4.8 ± 1.0 4.9 ± 1.0 0.771 5.0 ± 1.0 5.1 ± 1.2 0.983
Creatinine (mg/dL) 0.7 ± 0.2 0.7 ± 0.1 0.894 0.7 ± 0.2 0.7 ± 0.1 0.604
Sodium (mEq/L) 141 ± 2 141 ± 1 0.564 141 ± 2 141 ± 2 0.944
Chloride (mEq/L) 104 ± 2 103 ± 2 0.348 103 ± 2 104 ± 3 0.852
Potassium (mEq/L) 4.8 ± 0.5 4.9 ± 0.5 0.508 4.5 ± 0.5 4.4 ± 0.4 0.436
Calcium (mg/L) 9.3 ± 0.3 9.2 ± 0.4 0.238 9.3 ± 0.3 9.2 ± 0.4 0.293
Inorganic phosphorus (mg/dL) 3.4 ± 0.3 3.4 ± 0.5 0.955 3.4 ± 0.3 3.3 ± 0.5 0.386
Red blood cells (×10
4/μL) 439 ± 33 443 ± 32 0.643 433 ± 32 437 ± 28 0.596
White blood cells (/μL) 5493 ± 1270 5420 ± 1205 0.794 5258 ± 1362 5058 ± 1089 0.470
Platelet (×10
4/μL) 22.3 ± 4.4 21.9 ± 5.2 0.693 22.0 ± 4.1 21.0 ± 5.0 0.349
Hemoglobin (g/dL) 13.9 ± 0.9 13.9 ± 0.9 0.933 13.5 ± 0.9 13.5 ± 0.8 0.880
Hematocrit (%) 43.5 ± 2.7 43.6 ± 2.5 0.942 43.4 ± 2.9 43.6 ± 2.3 0.779
Mean (SD); n, number of subject; P value, by unpaired t-test.
14×1 0
9 cells of heat-killed L. pentosus strain b240 per day for 12 weeks.
Table 4 Accumulated incidents of adverse symptoms
reported by the subjects during the intervention period
Symptoms Placebo group
(n = 40)
b240 group
1
(n = 40)
P value
Common cold 4 (10.0%) 2 (5.0%) 0.396
Headache 1 (2.5%) 2 (5.0%) 0.556
Anorexia 2 (5.0%) 0 (0.0%) 0.152
Nasal discharge 4 (10.0%) 7 (17.5%) 0.330
Abdominal distension 0 (0.0%) 1 (2.5%) 0.314
Abdominal pain 0 (0.0%) 1 (2.5%) 0.314
Data are represented by number of symptoms (incidence of symptoms)
during the intervention period. P value, by the chi-square test.
14×1 0
9 cells of heat-killed L. pentosus strain b240 per day for 12 weeks.
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groups; blood profiles before and after the study, indi-
cating that the study had no consistent effect on the
blood components we examined. Furthermore, the num-
ber of incidents of unfavorable changes in the blood did
not differ between the 2 groups (data not shown). A
review of illness records over the intervention period
revealed no significant difference in adverse events
between the 2 groups; this is consistent with our pre-
vious results [26]. However, future studies using a larger
sample size are needed to confirm the safety of oral
intake of b240.
This study had several limitations. First, we excluded
inappropriate saliva samples that met pre-determined
exclusion criteria for data analysis. This procedure
resulted in different saliva sample sizes in the b240 and
placebo groups. However, exclusion/missing data
occurred less often in the b240 group than in the pla-
cebo group, and an alternative analysis (intention-to-
treat approach) using all available samples, including
potentially inappropriate samples, generated almost
identical results (data not shown). Second, this study
only included individuals who had never been smokers.
The results of this study therefore cannot be automati-
cally generalized to be applicable to smokers. Third, a
comparison with younger counterparts is lacking in this
study. In our previous report, however, we demonstrated
the beneficial effect of b240 on salivary IgA in young
adults [26], in which we used the same dosage of b240
(2 × 10
9 CFU/day), suggesting that all adults respond in
a similar fashion to oral b240 intake. However, a direct
comparison between young and older subjects may pro-
v i d e df u r t h e ri n f o r m a t i o no nt h eb 2 4 0m e c h a n i s mo f
action, e.g., normalization of the SIgA response in the
elderly or vice versa and the need to increase dosage
and time of administration for attaining normality.
Conclusions
This study has shown that b240 intervention increases
SIgA secretion in the saliva of elderly individuals.
Improved clinical endpoints as a product of mucosal
immunity may be achieved by increasing SIgA secretion.
It is now important to determine whether enhanced sali-
vary SIgA secretion could lead to increased protection
against infectious diseases such as URTI in the elderly.
Methods
Subjects
The research protocol was approved by the Ethics Com-
mittee of Tokyo Metropolitan Institute of Gerontology
(TMIG) (November 26, 2007). The study was conducted
in accordance with the Helsinki Declaration. The sub-
jects were recruited via a local advertisement for resi-
dents aged 65 years and over and residing in Itabashi
Ward, Tokyo. Before giving consent, the subjects were
given a detailed explanation of the purposes of the study
and potential risks of participation. A total of 115 indivi-
duals participated in the first-phase screening test (see
Assessment). The initial exclusion criteria were as fol-
lows: (1) current or former smoker; (2) vigorous (more
than 6 metabolic equivalents) exerciser; (3) showing
non-standard results in blood chemistry, blood pressure,
and pulse; (4) patients with hepatitis, cancer, inflamma-
tory bowel diseases, rheumatoid arthritis, and other dis-
eases affecting the digestive tract and immune system;
(5) patients with periodontitis and/or hemorrhagic sto-
matitis; (6) patients taking antibiotics; (7) patients taking
antiflatulents, antidiarrheic drugs, steroids, immunosup-
pressive drugs, and other drugs related to activation and
suppression of the digestive and immune systems; (8)
patients taking drugs potentially affecting saliva secre-
tion; and (9) patients declared ineligible for participation
by a medical doctor. Throughout the test, 21 out of the
115 participants were found to meet at least 1 of the
exclusion criteria and were excluded. The remaining 94
individuals underwent a second-phase screening test in
which they visited the study site twice on 2 different
days in a week and provided a total of 4 saliva samples
(2 samples per day × 2 days); the samples were used to
d e t e r m i n eS I g Al e v e l s .T h es a l i v ac o l l e c t i o na n dS I g A
determination method was identical to the methods
described below. According to the coefficient of variance
(CV) in the SIgA secretion rate of 4 saliva samples, we
further selected 80 individuals who showed relatively
low CVs. They included the subjects selected for the fol-
lowing randomized controlled trial (RCT) (Figure 4).
Protocol of the randomized control trial
The experiment was conducted from February to May
2008 as a randomized, placebo-controlled, double-blind
trial. 80 eligible subjects were randomly assigned to 1 of
2g r o u p s :t h eb 2 4 0g r o u p( n=4 0 )a n dp l a c e b og r o u p
(n = 40), matched for age and gender. The participants
were instructed to consume a beverage containing b240
or placebo daily at breakfast time for 12 weeks. On the
day of saliva collection, they were given a beverage imme-
diately after saliva collection. Saliva samples were col-
lected using the suction method at the same time of day
before (week 0) and every 2 weeks (weeks 2, 4, 6, 8, 10,
and 12) after study initiation. The subjects were also
instructed to record in a diary any symptoms experienced
and/or medications taken during the 12-week interven-
tion. This information was provided for the evaluation of
safety and eligibility for saliva sample procedures.
b240 and placebo beverage
A trial beverage containing 4 × 10
9 cells of heat-killed
b240 was prepared in 125 mL of sterile water as follows:
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Page 7 of 11After cultivating b240 in carrot juice and performing
repeated washing, viable cells were counted using the
colony counting method. The b240 cells were sterilized
in an autoclave for 15 min, diluted with sterile water to
a final concentration of 2 × 10
9 CFU/125 mL based on
viable cell counts. Then, total cell counts were deter-
mined as 4 × 10
9 cells/125 mL using flow cytometry.
Aliquots of 125 mL were placed in paper cups. A pla-
cebo beverage (125 mL of sterile water) was similarly
prepared. Both beverages had identical taste. The iden-
tity of the beverage consumed by each individual subject
was double-blinded until the end of the study.
Assessment
In the first phase of screening, all participants (n = 115)
were assessed with respect to their physical characteris-
tics [height, weight, body mass index (BMI)], blood
pressure, urine profile, oral health, functional capacity,
and physical fitness. For this purpose, the individuals
were interviewed by trained personnel on their medical
history, medications, TMIG-Index of Competence [43],
and Motor Fitness Scale [44]. All subjects underwent
urinalysis and blood tests and were examined for peri-
odontitis and hemorrhagic stomatitis by a dental hygie-
nist. We used this information as pre-intervention data
for the 80 RCT-eligible subjects. Additionally, the 80
subjects were examined for stress and mood, nutritional
intake, and physical activities by answering the Profile of
Mood States (POMS) questionnaire [45], the Brief Diet-
ary Habit Questionnaire [46,47], and the Japan Arterio-
sclerosis Longitudinal Study Physical Activity
Questionnaire [48]. Chromogranin A (CgA) in saliva
was also measured.
After the intervention, those who completed the RCT
(n = 80) were assessed again for all the items mentioned
above except for physical characteristics, blood pressure,
115 responded to recruitment advertisement
1st and 2nd phase
Screening for eligibility
35 excluded
21 met exclusion criteria
14 had higher CVs in SIgA
80 eligible subjects
Placebo group
(N = 40)
b240 group
(N = 40)
Saliva collection
week 0 (n = 79)
no saliva (n = 1)
week 2 (n = 78)
absence (N = 1)
week 4 (n = 80)
week 6 (n = 78)
absence (N = 1)
week 8 (n = 74)
absence (N = 3)
week 10 (n = 76)
absence (N = 2)
week 12 (n = 80)
Saliva collection
week 0 (n = 80)
week 2 (n = 79)
handling mistake
(n = 1)
week 4 (n = 80)
week 6 (n = 80)
week 8 (n = 72)
absence (N = 4)
week 10 (n = 80)
week 12 (n = 80)
Exclusion
week 0 (n = 10)
took forbidden
drug (N = 3),
changed affecting
drug (N = 1), or
poor compliance
(N = 1)
week 2 (n = 10)
week 4 (n = 14)
took forbidden
drug (N = 1), or
affecting drug
(N = 1)
week 6 (n = 14)
took forbidden
drug (N = 1)
week 8 (n = 14)
week 10 (n = 16)
took forbidden
drug (N = 1)
week 12 (n = 20)
took forbidden
drug (N = 1), or
affecting drug
(N = 1)
Analysis
week 0 (n = 70)
week 2 (n = 68)
week 4 (n = 66)
week 6 (n = 64)
week 8 (n = 62)
week 10 (n = 60)
week 12 (n = 60)
Exclusion
week 0 (n = 4)
took forbidden
drug (N = 1), or
changed affecting
drug (N = 1)
week 2 (n = 4)
took affecting
drug (N = 1)
week 4 (n = 10)
took forbidden
drug (N = 3), or
affecting drug
(N = 1)
week 6 (n = 8)
week 8 (n = 10)
took affecting
drug (N = 1)
week 10 (n = 10)
took forbidden
drug (N = 1)
week 12 (n = 14)
poor compliance
(N = 1), or took
affecting drug
(N = 1)
Analysis
week 0 (n = 76)
week 2 (n = 75)
week 4 (n = 70)
week 6 (n = 72)
week 8 (n = 62)
week 10 (n = 70)
week 12 (n = 66)
Figure 4 Flow of subjects and saliva samples through the trial. N, number of subjects; n, number of saliva samples; CV, coefficient of
variation. Saliva samples were collected twice per person every 2 weeks during the 12 week period. “Affecting drug” means that the drug, such
as an antihistamine, potentially affects saliva secretion. “Absence” means that the subject could not participate on the day of saliva collection
due to miscellaneous reasons. “No saliva” means that the subject was present but failed to provide a saliva sample.
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Page 8 of 11urine profile, oral health, functional capacity, and physi-
cal fitness.
From the subjects’ diaries, we collected information
regarding protocol compliance, occurrence of adverse
symptoms, and medications used throughout the inter-
vention period.
Blood tests and chromogranin A in saliva
Blood was tested for circulating cell counts (red blood
cells, white blood cells, and platelets), hemoglobin,
hematocrit, serum total protein, albumin, albumin/glo-
bulin ratio, total cholesterol, triglyceride, free fatty acid,
fasting glucose, hemoglobin A1c, aspartate aminotrans-
ferase, alanine aminotransferase, g-glutamyl transpepti-
dase, alkaline phosphatase, lactate dehydrogenase,
choline esterase, total bilirubin, direct and indirect bilir-
ubin, urea nitrogen, uric acid, creatinine, sodium, chlor-
ide, potassium, calcium, inorganic phosphorus, and
cortisol by standardized procedures at the Special Refer-
ence Laboratory Inc., Tokyo, Japan. CgA in saliva was
measured using the Human Chromogranin A EIA Kit
(Yanaihara Inst., Shizuoka, Japan), and total protein in
saliva was measured using a protein staining assay (Bio-
Rad Japan, Tokyo, Japan). CgA was evaluated by the
CgA/total protein ratio.
Saliva collection and SIgA detection
Saliva samples were collected every 2 weeks during the
12-week period, according to the method described by
Michishige et al. [37]. Subjects were asked to avoid alco-
holic beverages and to fast overnight before the test;
they gathered at a test site, consumed an identical
breakfast (250 kcal in energy), and rested in a seated
position until the initiation of saliva collection. 5 min-
utes before the sample collection, all the subjects rinsed
their mouths with distilled water 3 times, swallowed the
whole saliva, and fixed a plastic suction tube (TOP Co.,
Tokyo, Japan) in their mouth to allow aspiration of
fresh saliva for 5 min (SeaStar Co., Tokyo, Japan). After
a 15-min rest, saliva collection was repeated to yield 2
samples per individual. The amount of saliva in grams
was converted to milliliters assuming the density of sal-
i v at ob e1g / m L .A f t e rm easurement of the sample
weight, the saliva samples were frozen at -80°C and
stored until further use. SIgA concentration was mea-
sured by an enzyme-linked immunosorbent assay using
a commercial kit (Salivary Secretory IgA Indirect
Enzyme Immunoassay Kit; Salimetrics, PA, USA). The
intra-assay CV for SIgA concentration with a higher and
a lower value was 2.3% and 2.8%, respectively. The
inter-assay CV for SIgA concentration with a higher and
a lower value was 3.8% and 5.1%, respectively. Data
were expressed in 3 forms: (1) saliva flow rate per 5 min
(mL/5 min), (2) SIgA concentration (μg/mL), and (3)
SIgA secretion rate per 5 min (μg/5 min); the SIgA
secretion rate was calculated by multiplying the SIgA
concentration (μg/mL) by the saliva flow rate per 5 min
(mL/5 min).
Assessment of safety
We compared the accumulated incidents of adverse
symptoms occurring during the intervention and blood
profiles at pre- and post-intervention in the b240 and
placebo groups.
Statistical analyses
Before subject allocation, potentially inappropriate saliva
samples were excluded from the analysis on the basis of
the following exclusion/inclusion criteria: all samples for
a non-compliant subject and for 2 subjects who changed
antihistamine medications during the study period,
immediate samples for a subject who had several alco-
holic beverages in the evening prior to collection, all
samples thereafter for subjects who took antibiotics (n =
8), steroids (n = 1), and drugs related to the activation
of digestive tract function (n = 2), and immediate sam-
ples for 5 subjects who temporarily took antihistamines
shortly before saliva collection. These procedures yielded
af i n a ls a m p l es i z eo f6 6( w e e k1 2 )f o rt h eb 2 4 0g r o u p
(week 0 sample size, 76), and 60 (week 12) for the pla-
cebo group (week 0 sample size, 70) (2 saliva samples
were collected per person per day; Figure 4).
Salivary SIgA concentration, saliva flow rate, and SIgA
secretion rate were analyzed separately. The differences
between the b240 and placebo groups for each variable
were analyzed by multiple-factor ANOVA (factors:
group, gender, period of intake, and frequency of saliva
collection). The comparison between the b240 and pla-
cebo groups with respect to age, height, weight, BMI,
serum cortisol, CgA/total protein ratio, stress assess-
ment, nutritional intake, and daily physical activities
were analyzed by the unpaired t-test. The unpaired t-
test was applied to the comparison of blood variables
pre- and post-intervention and the chi-squared test was
applied to compare the accumulated incidents of
adverse symptoms between groups. A two-tailed P-value
<0.05 was accepted as significant for all tests. Data were
analyzed using SAS software (R8.1 or R9.1, SAS Insti-
tute, Japan).
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